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Abstract: The liver mass constitutes hepatocytes expressing receptors for vitamin B12 (B12)-bound
transporters in circulation. However, intrahepatic and circulating B12 interrelationship levels remain
unclear. We assessed the intracellular B12 levels at various circulating B12 concentrations in human
HepG2 cell-line and liver tissue levels of B12 in the C57BL/6 mouse model. In HepG2 cells treated
with a range of B12 concentrations, the intracellular and circulatory B12 levels, transcript and protein
levels of B12 receptor (CD320) and transporter (TCN2) were determined using immunoassays, qRT-
PCR and Western blot, respectively. Similar assessments were done in plasma and liver tissue of
C57BL/6 mice, previously fed a diet of either a high or low B12 (30.82 µg B12/kg and 7.49 µg
B12/kg, respectively) for 8–10 weeks. The physiological B12 status (0.15–1 nM) resulted in increased
levels of intracellular B12 in HepG2 cells compared to supraphysiological levels of B12 (>1 nM).
Gene and protein expression of CD320 and TCN2 were also higher at physiological levels of B12.
Progressively increasing extracellular B12 to supraphysiological levels led to relative decreased levels
of intracellular B12, lower expression of gene and protein levels of CD320 and TCN2. Similar results
were observed in liver tissue from mice fed on a low B12 diet verses high B12 diet. These findings
suggest that unlike supraphysiological B12, physiological levels of B12 in the extracellular media
or circulation accelerates active transport of B12, and expression of CD320 and TCN2, resulting in
higher relative uptake of B12 in hepatocytes.
Keywords: vitamin B12 (cobalamin); transcobalamin; hepatocytes; intrinsic factor; B12 receptor
(CD320); B12 transporter (transcobalamin II, TCN2)
1. Introduction
Vitamin B12 (B12), also known as cobalamin (Cbl), is an essential water-soluble vi-
tamin that is involved in cell metabolism. The main sources of B12 are animal products,
supplements or fortified foods. B12 is difficult to produce chemically and is only naturally
synthesized by fermentation with cobalamin-producing bacteria. Although some ruminat-
ing mammals absorb the B12 from the bacteria living in their gastrointestinal tract (GIT),
humans cannot acquire the B12 from their enteric bacteria despite the large colonies, as they
live primarily in a large intestine [1]. Intestinal uptake of B12 occurs in a small intestine,
mainly aided by the binding of a gastric intrinsic factor (IF) with only 1% of free B12 known
to be passively absorbed through the GIT [2]. Hence, humans rely mainly on the dietary
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sources of B12. However, the circulating levels of B12 are dependent on its receptors and
transporters. Specific membrane receptors (CD320) and transport proteins (haptocorrin
(HC) and transcobalamin II (TCN2)) facilitate the uptake and delivery of B12 to the liver
(B12-HC) and other tissues (B12-TCN2) in humans [3]. Dietary uptake of B12 occurs by the
sequential binding to HC and IF, followed by the uptake of B12-IF via specific ileal recep-
tors (Cubilin) [4], then B12 is released into the bloodstream to form a B12-TCN2 complex,
which becomes actively available for tissue uptake via the transcobalamin receptor CD320.
Consequently, reduced intake or intestinal absorption of B12 can result in deficit levels
of B12 tissue stores. Several studies show that B12 deficiency is associated with various
metabolic and neurodevelopment diseases and is treated with oral supplementation.
TCN2 is the most essential protein in the delivery of B12 from the blood to various
tissues and organs. The potential role of TCN2 in the transport of B12 from the mother to
the foetus was reported in pregnant adolescents, where higher placental TCN2 expression
was associated with higher cord blood B12 concentrations [5]. The transcobalamin recep-
tor (CD320) is known to be expressed in actively dividing cells [6] and required for the
uptake of TCN2-bound B12 [7]. Studies have also shown that CD320 knockout mice have
B12 deficiency and have behavioural abnormalities, macrocytic anaemia, infertility and
hypomethylation of DNA in the brain [8]. However, current knowledge on the absorption
and tissue distribution of B12 has only been reported in few animal studies [9–14]. A study
in Wistar rats showed that kidneys contained more B12 compared to other tissues such as
lungs, spleen, brain, heart and liver [15]. B12 depleted rats have shown that the uptake of
hydroxy-Cbl in the liver was more than that for cyano-Cbl, contrary to other tissues such
as the kidney, brain and spleen [10]. Similarly, animals fed with imbalanced nutrients (low
B12, high folate and high methionine) during pregnancy showed a redistribution of B12 in
the maternal tissue from the kidneys to the liver and in the foetal compartment (uterus,
placenta and foetuses) [16]. These studies evidenced that the receptors/transporters corre-
lated to B12 levels and the differential tissue distribution depends on the B12 status. As
TCN2/CD320 are the key transporter/receptor for B12 in many tissues, studying the levels
of these two may likely provide an understanding of the relative cellular uptake of B12.
Moreover, the role of receptor/transporter in modulating the intracellular levels of B12 at
various levels of circulating B12 levels has not been explored. Liver is the main storage
site and metabolic factory for B12 [17]. It is, however, not clear whether B12 transporters
and receptors regulate hepatic B12 levels in relation to the circulating B12 levels. There is
currently no data that elucidates the role of CD320 and TCN2 with intracellular levels of
B12 in hepatocytes. Therefore, the present study was designed to assess and understand
the relationship between circulating the B12 level, its intracellular hepatic concentrations
and the levels of CD320 and TCN in both the in vitro (human) and in vivo (mouse) model
of liver.
2. Results
2.1. Intracellular and Tissue Levels of B12
2.1.1. Intracellular B12 Level in Hep G2 Cell Line
At low (0.025–0.1 nM) and physiological levels of extracellular B12 concentration
(1 nM), the intracellular B12 levels (0.07–0.15 nmol/g protein) were relatively higher.
However, supraphysiological levels of extracellular concentration of B12 (10 nM, 20 nM,
50 nM, 100 nM, 200 nM, 400 nM and 500 nM) resulted in only a slight increase in the
intracellular B12 levels (i.e., 0.24, 0.45, 0.68, 0.73, 1.91, 2.33 and 3.99 nmol/g protein,
respectively) (Figure 1A). Thus, we found that though there was a 20,000-fold increase in
the extracellular B12 concentration (i.e., from 0.025 to 500 nM B12), the intracellular B12
level showed only 57-fold increase (i.e., from 0.07 to 3.99 nmol/g protein). Our results
suggest that the efficiency of B12 transport (related to the extracellular level of B12) is
reduced at supraphysiological levels of B12 (>1 nM). However, physiological levels of
B12 are not accompanied by a tremendous reduction in the intracellular B12 because the
transportation system has a high affinity for B12 and hence improves the rate of its uptake.
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2.1.2. Int cellul r B12 L vel in Mice Liver Tissues
To evaluate the tissue-specific relative uptake of B12, we assessed the levels of B12
in extracts of liver tissue relative to plasma. The average B12 concentration in the plasma
of mice with low B12 (LB (n = 6)) was 0.82 nM (physiological level) and the tissue extract
was 18 nmol/g protein. In contrast, the average concentration in the high plasma B12 (HB
(n = 6)) group was 5.36 nM (supraphysiological level) and the tissue extract level of B12
was 34 nmol/g protein (Figure 1B). Like the in vitro model, we observed whilst there was
a 6.5-fold increase (i.e., 0.82–5.36 nM) in the plasma B12 concentration, the tissue extract
resulted in only a 2-fold increase (i.e., 18–34 nmol/g protein) in B12 concentration.
2.2. B12 Transcobalamin Receptor (CD320)
2.2.1. Hep G2 Cells
We assessed the protein and mRNA expression of CD320 in the Hep G2 cell line at ten
different B12 media concentrations. In the experiment with low and physiological levels of
extracellular B12 concentrations (0.025–1 nM), the gene expression of the CD320 receptors
was significantly higher compared to the control (500 nM). At supraphysiological levels of
B12 media concentrations (10 nM, 20 nM, 50 nM, 100 nM, 200 nM and 400 nM), however;
there was a decrease in the gene expression of transcobalamin receptor (CD320), with no
significant difference from the control (extracellular B12 = 500 nM) (Figure 2A). Similarly,
at media concentrations of B12 (such as 0.025 nM, 0.1 nM, 10 nM and 20 nM), we observed
upregulation of CD320 protein levels compared to the control. The highest CD320 protein
expression was observed in cells cultured at the lowest B12 media concentration (0.025 nM).
However, cells cultured at supraphysiological levels of B12 media concentrations (such as
50 nM, 100 nM, 200 nM and 400 nM) had decreased CD320 protein levels with no significant
difference from the control (500 nM) (Figure 2B).
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liver tissues: (A) The mRNA expression of transcobalamin receptors (CD320) normalized to 18S
rRNA endogenous control and (B) CD320 protein levels related to β-actin in Hep G2 cells at ten
different B12 concentrations (500 nM (control), 400 nM, 200 nM, 100 nM, 50 nM, 20 nM, 10 nM,
1 nM, 0.1 nM and 0.025 nM). (C). The CD320 mRNA expression in liver tissues of HB and LB mice
normalized to L19 endogenous control and (D) CD320 protein levels related to β-actin in liv r tissues
of HB and LB mice. The da a are representative of mean ± SEM (n = 6) and * indicates significance
compared to the control; * p < 0.05, ** p < 0.01, *** p < 0.001.
2.2.2. Mice Liver
Then, we assessed the mRNA expression and protein levels of CD320 in the liver
tissue extracts of mice with high and low levels of B12 (HB and LB, respectively). There
was no significant difference in the CD320 mRNA expression between the LB and HB mice
(Figure 2C). However, we observed that the CD320 protein levels in the tissue extracts
of LB mice (at physiological levels) were significantly increased compared to the HB
group (supraphysiological levels) (Figure 2D). This suggests that although the difference in
expression of B12 receptors was not obvious at the transcript level, the protein expression
was significantly higher in the LB group implying that modifications could have occurred
at the post-translational level in mice liver.
2.3. B12 Transporter Transcobalamin II (TCN2)
2.3.1. Hep G2 Cells
To further evaluate the transport of B12, we assessed the protein and mRNA expression
of B12 transporter transcobalamin II (TCN2) in Hep G2 cell line cultured in ten different
B12 media. At media B12 conditions (0.025–0.1 nM), mRNA expression of hepatic TCN2
was significantly higher. In contrast, we observed that mRNA expression of TCN2 was
decreased as concentrations of B12 increased (such as 1 nM, 10 nM, 20 nM, 50 nM, 100 nM,
200 nM and 400 nM), showing no significant difference from the control. The highest
TCN2 mRNA expression was observed at the lowest B12 media concentration (0.025 nM)
compared to the control (Figure 3A).
Similarly, cells cultured at media concentrations of B12 (0.025–50 nM) resulted in high
TCN2 protein expression compared to the control. However, supraphysiological levels B12
media concentrations (such as 100 nM, 200 nM and 400 nM) showed low levels of TCN2
protein expression that were not significantly different from the control (Figure 3B).
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G2 and liver tissues: ( ) The expression of TCN2 in Hep G2 normalized to 18S rRNA
endogenous control and (B) protein level of TCN2 related to β-actin in Hep G2 at ten different B12
media concentrations (500 nM (control), 400 nM, 200 nM, 100 nM, 50 nM, 20 nM, 10 nM, 1 nM, 0.1 nM
and 0.025 nM). (C) The TCN2 mRNA expression in liver tissues of HB and LB mice normalized to L19
endogenous control and (D) represents the levels of B12 transporter TCN2 protein related to β-actin
in HB and LB groups of mice. The data are representative of mean ± SEM (n = 6), and * indicates
significance compared to the control; * p< 0.05, ** p< 0.01, *** p< 0.001.
2.3.2. Mice Liver
Like with Hep G2 cells, we observed that both mRNA expression and protein levels
of TCN2 were significantly higher in the tissue extracts of mice with a low plasma B12
(LB) compared to the HB group. The LB group (at physiological levels of B12) showed
the expression of mRNA and protein of TCN2 to be 75% (Figure 3C) and 50% (Figure 3D)
higher respectively, compared to the HB mice.
3. Discussion
In this study, both the in vitro and in vivo model demonstrate that physiological
extracellular B12 concentrations led to an increased relative uptake of B12 than supra-
physiological B12 levels. Both gene and protein expression of B12 receptor CD320 and
transporter TCN2 also increased at physiological B12 concentrations. These results thus
imply that physiological levels of B12 in the extracellular medium (or blood plasma) induce
hepatocytes to accelerate the expression of B12 receptor CD320 and transporter TCN2, and
cellular uptake of B12.
Both higher and lower concentrations of circulating are common. For insta ce,
B12 deficiency may be caused by v getaria ism, prolonged metformin treatment in type 2
diabetes patients a d during pregnancy [18,19], whereas high plasma levels may re ult from
ingestion of B12 supplement [20]. B12 leve range from low (0.025–0.1 nM), physiological
(0.1–1 nM) and supraphysiological (>1 nM) levels. In the current study, we determined
the intracellular levels of B12 in Hep G2 cells cultur d in ten different B12 media to asse s
how liver cells may respond to lower, physiological and supraphysiological levels in
humans. We found that the increasing extracellular B12 does not stimulate an indefinite
or a dose-dependent increase of the intracellular B12 because of a limited capacity of the
transportation system, which becomes saturated and then downregulates its rate. The
saturable character of B12 uptake was also found in the intestine [21], though up- and
downregulation of transporters was not demonstrated. A study in the rat model showed
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that several small doses of dietary B12 are more efficient in increasing blood and tissue B12,
than a single large dose [11]. In a human study, Yajnik et al. showed that supplementation
with a physiological dose of oral B12 over 11-months in asymptomatic low B12 adolescent
women significantly improved the B12 levels in these women. [22]. A recent study in early
postpartum women in urban Tanzania showed that B12 was low in breast milk and was
not significantly increased by high dose supplementation [23]. Our data may also suggest
that the supraphysiological levels of B12 in blood induces only a moderate to low increase
in the intracellular B12 and may not be required for further cellular uptake.
Importantly, we observed increased protein and gene expression of the B12 receptor
(CD320) in Hep G2, particularly at physiological circulating B12 levels. In contrast, supra-
physiological B12 media concentrations resulted in a lower expression of protein CD320,
though there was no significant difference in the mRNA expression, revealing that mRNA
expression of a gene does not always predict its protein level [24]. Our findings are in
line with an earlier study in hepatocytes, which showed that modulations in the cellular
uptake of B12 was dependent on the phases of the cell cycle and alterations in the number
of cellular receptors rather than affinity [25]. In this study, we also observed higher TCN2
levels in both Hep G2 cell line and in mice under decreasing concentrations of extracellular
B12 and vice versa. B12 transporter—TCN2 is principally produced by the kidneys and
hepatocytes, intestines, endothelia and monocytes [26–28]. De novo biosynthesis of TCN2
has been demonstrated in the liver perfusates and cultured liver parenchymal cells using
rat models [29,30], supporting our observation. Although TCN2 accounts for approxi-
mately 22–37% of plasma B12 [31], it is the key transporter of up to 99% of active B12
(holo-TC) into the tissues due to its fast turnover [32]. Therefore, modulations in both gene
and protein expression of TCN2 in the liver reflects its role in the regulation of B12 uptake
and metabolism. Supporting our findings, an animal study showed that low B12 increased
the expression of TCN2 in the maternal and foetal tissues [33]. Clinically, low plasma B12
may be observed during pregnancy due to increased demand of B12 for foetus [34], and
some perturbation in the receptor or/and transporter might be expected. For example, a
recent study showed a progressive increase in serum levels of soluble CD320 receptors up
to 35 weeks of gestation [35]. High levels of serum sCD320 receptors during pregnancy
might be derived from the placenta, where higher expression of the receptor has been
shown [35]. Taken together, our data highlight that the intracellular B12 levels could be
maintained by upregulation of B12 uptake at its limited supply and downregulation at
an excessive supply. All in all, such mechanisms may shunt the excess of B12 out of its
cells for mobilization to other tissues where it is most needed. In case of B12, the liver and
kidneys are typical organs that dramatically change their intracellular levels depending
on extracellular supply of B12 and the requirement of the cells [9]. It should be, however
noted, that different forms of B12 (e.g., cyano- vs. hydroxo-B12) can give different ratios of
intracellular/extracellular vitamin if administered at equal quantities [9]. Possible expla-
nation may be that the different conversion rates of the inactive form of B12 to the active
form, where the unprocessed inert B12 forms are expelled [9].
4. Materials and Methods
4.1. Cell Culture
The cell culture was performed with slight modifications, as described elsewhere [36].
Briefly, the HepG2 cell line was cultured using custom-made B12 deficient Eagles’ minimal
essential medium (EMEM). The medium was supplemented with 10% foetal bovine serum
(FBS), 1% penicillin/streptomycin, 1% L-glutamine and placed under 37 ◦C incubation
with 5% CO2 saturation. At 90% confluence, the cells were trypsinized and seeded in 6-well
plates at 75,000 cells per well and incubated with a range of different concentrations of B12
in the media, i.e., 500 nM (control), 400 nM, 200 nM, 100 nM, 50 nM, 20 nM, 10 nM, 1 nM,
0.1 nM and 0.025 nM B12. The media in each well was changed every 48 h. When the cells
reached 90–100% confluence, they were harvested and stored at −80 ◦C for further protein
and gene expression analysis.
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4.2. Animal Model
All animal procedures were carried out in accordance with the United Kingdom
Animals (Scientific Procedures) Act 1986, approved by the local ethics review committee at
the University of Southampton and conducted under Home Office Project Licence number
70/6457, granted on 10 May 2017. Female C57/BL6J mice were maintained under a 12 h
light/dark cycle (lights on at 07.00 h), and at a constant temperature of 22 ± 2 ◦C with
food and water available ad libitum. The mice (n = 6 per group) were fed either a control
diet containing 7.49 µg/kg vitamin B12 (SDS RM1 diet, LBS-Serving Biotechnology Ltd,
Surrey, UK) or a high vitamin B12 diet containing 30.82 µg/kg vitamin B12 (SDS 824053
Diet, LBS-Serving Biotechnology Ltd, Surrey, UK) for 8–10 weeks. The animals were killed
by cervical dislocation. The blood and liver tissue samples were collected. Plasma was
extracted from the K2-EDTA blood samples and stored at −20 ◦C, and liver samples were
immediately placed on ice and carefully diced, followed by washing in Hanks balanced
salt solution (HBSS, Merck Life Science UK Ltd, Dorset, UK) until all blood was removed.
Samples were subsequently snap frozen in liquid nitrogen and stored at −80 ◦C for further
analysis.
4.3. RNA Isolation and Quantitative Real Time-PCR (qRT-PCR)
Total RNA in Hep G2 cells and mice liver tissues of different concentration of B12
were isolated using Qiazol (Qiagen, Manchester, UK) according to the manufacturer’s
instruction. RNA quantification, quality and integrity (260/230 and 260/280 ratios and con-
centrations) were carried out using a NanoDrop spectrophotometer (Labtech, Heathfield,
UK). Total RNA (300 ng) was reverse transcribed to cDNA using reverse M-MLV transcrip-
tase (ThermoScientific, Loughborough, UK). Gene expression of CD320 in the Hep G2 cell
line (CD320: cat no Hs00213164_m1; TCN2: cat no Hs00165902_m1; Applied Biosystems,
Thermo Fisher Scientific, Horsham, UK) and mice liver tissues (CD320: forward primer—
GGTCCAAGTCTCCGGCTCTA-, reverse primer–AGCACATGACTCAATCCTACAGT;
TCN2: forward primer—CTTTGCTGGATCTTCCTTGG, reverse primer—TCCTGGGGTTT
GTAGTCAGC; Merck Life Science UK Ltd, Dorset, UK) were determined by quantitative
real time polymerase chain reaction (Applied Biosystems 7500 Fast Real-Time PCR Thermal
Cycler, Thermo Fisher Scientific, Horsham, UK). The housekeeping genes, 18s rRNA in the
HepG2 cell line (cat no 4319413E; Applied Biosystems, Thermo Fisher Scientific, Horsham,
UK) and L19 in mice liver tissues (forward primer—GGAAAAAGAAGGTCTGGTTGGA,
reverse primer—TGATCTGCTGACGGGAGTTG; Merck Life Science UK Ltd, Dorset, UK)
were used to determine relative gene expression.
4.4. Western Blot Analysis
Hep G2 cells in plates were washed twice with ice-cold phosphate-buffered saline (PBS)
followed by extraction buffer (RIPA—radioimmunoprecipitation assay buffer) containing
phosphatase and protease inhibitors. After lysis, insoluble materials were removed by
centrifugation and the supernatant was transferred to a new tube and kept at −80 ◦C for
further analysis [18]. Similarly, proteins were extracted from mouse liver tissues by adding
ice-cold RIPA buffer to the tube containing the tissue and then homogenised. Following
centrifugation, the supernatant was transferred to a fresh tube and kept at −80 ◦C for
further analysis. Protein content in the samples was quantified using the Bradford assay
(Bio-Rad Laboratories Ltd, Watford, UK). Western blots were carried out from both Hep
G2 cells and liver tissues using the protocol described elsewhere [19].
4.5. Measurement of B12
Hep G2 cells were washed twice with ice-cold phosphate-buffered saline (PBS). The
cells were then harvested or lysed in PBS and stored at −80 ◦C. Mice liver extracts were
obtained by homogenising the liver tissues in PBS and stored at −80 ◦C. Intracellular
concentrations of B12 in Hep G2 cell lysates, liver tissues and plasma were determined by
electrochemiluminescent (ECL) immunoassay kit (compatible to blood plasma, tissue and
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cellular levels of B12) using a Roche Cobas immunoassay analyzer (Roche Diagnostics Ltd,
West Sussex, UK). In cell culture media without supplemented B12, foetal bovine serum
(10% FBS) contributed less amounts of B12 (28 pM) to the media, which is well below the
physiological level (0.15–1 nM). The measuring range of the B12 kit was 0.037–1.476 nM.
Some of the cell line and tissue samples were in nanometre levels of B12, therefore, sam-
ples with B12 concentrations above the measuring range were diluted manually (several
folds) with Diluent Universal. After dilution, the results were multiplied by the dilution
factor. Following the manufacturer’s recommendation, a linearity assay was performed
using a known low analyte containing plasma as standard. The final measurements were
obtained in triplicates for every sample (n = 6 for each experimental condition) to ensure
reproducibility, and B12 concentrations were obtained by multiplying the average by the
dilution factor.
4.6. Statistical Analysis
Results are presented as mean ± standard error of the mean (SEM) for in vitro experi-
ments (n = 6) and in vivo samples (n = 6). Data for all samples obtained were tested for
normality, prior to analysis, with the Kolmogorov–Smirnov and Shapiro–Wilk normality
tests using Prism 8 (GraphPad Software, San Diego, CA, USA). Differences between either
parametric groups or non-parametric groups were observed respectively by performing
Student’s t-test or Mann–Whitney U test. p values of <0.05 were considered statistically
significant.
5. Conclusions
In conclusion, our study highlights that when extracellular B12 levels are at physiolog-
ical levels, the intracellular B12 levels are higher, which is supported by the increased gene
and protein expression of receptor/transporter in both in vitro and in vivo models. This
shows that at physiological B12 concentration, the active transport of B12 in the tissues
accelerate. Our evidence thus validates the long-existing hypothesis that the cells indeed,
regulate the uptake of B12. However, at supraphysiological levels of B12, the intracel-
lular concentrations are relatively reduced, the receptor/transporter get downregulated,
presumably to protect the cells from long-term exposure to high levels. This supports
that regular smaller doses of B12 supplementation might be better than larger, infrequent
dosing of B12 in deficient individuals. In addition, overloading B12 deficient patients with
supplements may not present any additional benefit but regular monitoring of patients to
aim for physiological levels may be recommended. This may maintain optimal levels of
the transporter/receptor system across various tissues, although this requires additional
studies in other tissues.
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